Market: median 1d +0.0% · breadth 19.7% advancing across 188 names
Data as of — announcements 2026-07-31 · flow 2026-07-28 · prices 2026-07-30
New today: 4DX, AR1, AR9, ARR, CUF, FMG, GL1, MML, PNN, RAP, SGQ, ZMI. New names versus yesterday's letter, so a continuing story doesn't read as fresh news.
Read these (6)
Today's announcements worth minutes, not seconds — triaged by deterministic rules (a raise, a result into live flow, quantified materiality). The LLM annotates; it never picks the bucket.
4DMedical delivered record quarterly scan volumes (+43% YoY) and marked a critical inflection with SimonMed Imaging's three-year, no-evaluation-phase commercial deployment across 170+ US outpatient centres, alongside peer-reviewed evidence (AJRCCM) validating CT:VQ for lung surgery patient selection (76% vs 46% response rate). Post-quarter acquisitions (contextflow, RevealDx partnership, Azra AI) and the US$20m Veterans Affairs pilot authorization indicator aggressive geographic and clinical expansion into acute pulmonary embolism and lung cancer screening.
Materiality: SimonMed agreement + GSK contract + contextflow acquisition + VA authorization collectively represent material pipeline expansion for a $2.075bn market-cap company transitioning from clinical proof-of-concept to scaled commercial deployment; insufficient data on incremental revenue contribution to quantify precisely
Priced in? Stock down 21% over 20 days pre-announcement; no run-up into quarterly; result appears to contain material new operational progress (SimonMed launch, contextflow close, VA bill) not yet reflected
AR1 delivered solid Q2 operational execution with 1.8kt copper production and $31m in cathode sales, supported by $71.6m cash, while high-grade Snow Queen drilling (7.5%+ Cu) indicators meaningful exploration upside. However, net operating cash burn of $6.8m despite strong sales revenue and acid supply constraints underscore near-term margin pressure, though the Anthill Project Agreement termination post-quarter simplifies ownership and future guidance.
💰Copper cathode production Q2 2026: 1,796 tonnes · Cash from copper sales: $31.0m · Cash at bank (end Q2): $71.6m · Snow Queen drillhole 26SQRC001: 10m @ 7.52% Cu, 9.28g/t Ag, 0.25g/t Au
Materiality: Quarterly production and cash position are core operational metrics for a $162m market cap copper producer; $71.6m cash provides ~7–8 quarters of runway at current burn, and Snow Queen discovery could materially expand resource base pending follow-up drilling.
Priced in? Stock down 11% over 20d and 7% over 5d into the report; weak pre-announcement sentiment suggests market was concerned about production or cash burn—execution updates and exploration upside may partially offset near-term headwinds.
archTIS delivered record FY26 contracted sales ($14.1M, +65% YoY) and strong ARR growth (+209%) post-Spirion integration, with U.S. DoD NC Protect passing all 60 production tests and Australian Defence awarding a $3.2M Kojensi contract. The business is transitioning from customer concentration (Top 10 halved to 32.3%) and Australian Defence dependency (16.6% of revenue) toward diversified recurring licensing, though negative Q4 operating cash flow (-$3.8M including integration costs) and tight liquidity ($2.9M cash) require sustained contract execution.
Materiality: Australian Defence contract ($3.2M, ~13% of FY26 contracted sales) and U.S. DoD NC Protect validation are material for $25M market cap; deferred revenue ($8.9M, +40%) covers ~6 months visibility; recent 20-day decline of -27% suggests market has been pricing in execution risk despite strong fundamentals.
Priced in? Stock down 27% over 20d and 8% over 5d into this result; strong topline beats (+92% Q4 revenue, +209% ARR) and landmark U.S. DoD clearance may have been partially discounted by prior weakness, but integration costs and negative operating cash flow likely weighed on sentiment.
ARR executed a procedurally solid Q2, advancing Final FS drilling (8/19 holes complete), structuring a three-stage pilot plant pathway with external partners (WRI, DISA, SRC), and strengthening executive depth ahead of a planned NASDAQ listing. Progress is methodical and operationally focused rather than news-driven, with no material resource or reserve upgrade announced.
💰FS drilling program: 3,050 m HQ core across 19 holes; 1,045 samples for assay · Pilot plant stages: 3-stage pathway: milling → mineral separation → oxide refining · Halleck Creek land package: 8,108 acres · Leadership additions: CDO (Conover), Director Projects & Engineering (Cable), NED (Gili post-regulatory approval)
Materiality: Insufficient data (no cash position, burn rate, or capex guidance disclosed in excerpt). Leadership appointments and pilot plant agreements are strategic but non-binding; FS drilling is early-stage (8 of 19 holes).
Priced in? Stock down 3% over 20d and 5d (no run-up); announcement released post-quarter-end on 31 Jul; typical quarterly cadence suggests limited surprise factor.
CuFe secured a significant $15.3m strategic placement from Pan African Resources and released an expanded Orlando scoping study with $705m NPV, while materially upgrading resource confidence at Gecko (Indicated resources now 66% vs 4%). The combined equity infusion and improved project economics position CuFe to fund near-term drilling and feasibility progression.
Materiality: Placement = ~14% of $108m market cap; Orlando NPV (55% share ≈ $388m) implies substantial leverage to commodity prices; cash injection material for funding exploration pipeline without immediate dilution.
Priced in? Stock down 15% over 20d and 9% over 5d into announcement; core scoping study released 6 May 2026 and Gecko MRE update 18 June; placement and executive appointment are new; mixed indicator suggests some anticipation of fundraising but recent selloff limits price-in.
Who bought and sold, by broker cohort, on a T+3 lag — spikes vs each stock's own baseline, multi-session streaks, and warnings where 'buying' is likely someone absorbing an exit.